

Syndicate Room: Video Interview with Paul Colbon

Our CEO and Co-founder Paul Colbon recently sat with SyndicateRoom to discuss the progress of Liverpool ChiroChem since our [funding round](#) on their [equity investment platform](#) in 2015. He started with a quick introduction about what we do, an overview of how our team works and a quick discussion of some of our unique selling points.

Paul then went on to discuss the ins and outs of how we have used the funds raised on SyndicateRoom, with particular focus on the R&D team in the UK, the sales & marketing team and establishing a production laboratory just outside of Shanghai in China.

He gave viewers a taster of what's planned in the immediate future, and longer term goals for LCC. The short term will see us focus on investment into the production laboratory and the R&D team, to ensure we stay at the forefront of the drug discovery market. In the longer term, we are looking to branch out into a few different areas based on the success of our chiral technologies. Our customer base has already asked for some specific developments in this area, particularly linked with the central nervous system (CNS). We will also focus on later stage drug development.

Paul shared his experience about working with those who invested in LCC through SyndicateRoom. and how much feedback and guidance they have offered on the business development and commercial side of the business. Paul hinted that to ensure production can be scaled up, and in order to accelerate the growth of the company, a further funding round will be needed in the future.

Hear from Paul himself, and watch the entire video below:

